Journal
NEUROLOGY INDIA
Volume 68, Issue 5, Pages 1192-1195Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0028-3886.299174
Keywords
Acute demyelinating encephalomyelitis (ADEM); Covid-19; SARS-Cov-2Key Message; ADEM (acute demyelinating encephalomyelitis) can occur in patients with severe Covid-19 infection; with increased complications and morbidity; Early recognition and treatment with corticosteroids may be beneficial
Categories
Ask authors/readers for more resources
Objective: The purpose of this study was to report three patients COVID-19 infection with severe respiratory syndrome requiring intubation, who developed acute demyelinating encephalomyelitis (ADEM). Methods: Patient data were obtained from medical records from the North Memorial Hospital, Robbinsdale, MN, USA. Results: Three patients (two men and one woman, aged 38-63) presented with fatigue, cough, and fever leading to acute respiratory distress syndrome secondary to COVID-19 infection requiring ventilatory support. Two patients were unresponsive and the third patient had severe diffuse weakness. MRI in all patients showed findings consistent with ADEM. CSF showed elevated protein in all patients with normal cell count and no evidence of infection, including negative COVID-19 PCR. All three patients were treated with intravenous corticosteroids and one improved markedly. The other two had minimal response to steroids and no further improvement after IVIG. Conclusion: Neurological complications from COVID-19 are being rapidly recognized. Our three cases highlight the occurrence of ADEM as a postinfectious/immune-mediated complication of COVID-19 infection, which may be responsive to corticosteroid treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available